Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Oppenheimer Maintains Outperform on 89bio, Lowers Price Target to $40

Author: Benzinga Newsdesk | May 13, 2022 08:24am

Oppenheimer analyst Jay Olson maintains 89bio (NASDAQ:ETNB) with a Outperform and lowers the price target from $49 to $40.

Posted In: ETNB

04/22/2024 Innodata Inc. (INOD)

04/23/2024 Lantronix, Inc. (LTRX)

AnaptysBio Inc (ANAB)